• IceCure outlined U.S. commercialization plans for its ProSense cryoablation system, positioned as the only on-label minimally invasive local treatment for low-risk breast cancer.
• Management pegged the U.S. breast cancer opportunity at more than $1.2 billion in total addressable market, citing an 8+ year competitive head start.
• ICE3 breast cancer study data cited 4.3% ipsilateral recurrence at 5 years, 96.7% survival, 24-hour recovery, no re-excision.
• FDA-cleared post-marketing ChoICE study planned for about 400 patients at at least 30 U.S. sites, with initiation targeted for H2 2026.
• Company cited regulatory approvals in 27 countries, 47 granted patents, 64 employees, manufacturing capacity positioned to scale.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief on July 12, 2026, and is solely responsible for the information contained therein.